Serum markers of cardiac complications in a systemic sclerosis cohort.

Autor: Tennøe AH; Department of Rheumatology, Oslo University Hospital, Postbox 4959, 0424, Nydalen, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Anesthesiology, Stavanger University Hospital, Stavanger, Norway., Murbræch K; Department of Cardiology, Oslo University Hospital, Oslo, Norway., Didriksen H; Department of Rheumatology, Oslo University Hospital, Postbox 4959, 0424, Nydalen, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Ueland T; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway., Palchevskiy V; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Weigt SS; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Fretheim H; Department of Rheumatology, Oslo University Hospital, Postbox 4959, 0424, Nydalen, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Midtvedt Ø; Department of Rheumatology, Oslo University Hospital, Postbox 4959, 0424, Nydalen, Oslo, Norway., Garen T; Department of Rheumatology, Oslo University Hospital, Postbox 4959, 0424, Nydalen, Oslo, Norway., Brunborg C; Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway., Aukrust P; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Inflammatory Research Center, University of Oslo, Oslo, Norway.; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway., Molberg Ø; Department of Rheumatology, Oslo University Hospital, Postbox 4959, 0424, Nydalen, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Belperio JA; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Hoffmann-Vold AM; Department of Rheumatology, Oslo University Hospital, Postbox 4959, 0424, Nydalen, Oslo, Norway. a.m.hoffmann-vold@medisin.uio.no.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. a.m.hoffmann-vold@medisin.uio.no.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 Mar 18; Vol. 12 (1), pp. 4661. Date of Electronic Publication: 2022 Mar 18.
DOI: 10.1038/s41598-022-08815-8
Abstrakt: Primary cardiac involvement is one of the leading causes of mortality in systemic sclerosis (SSc), but little is known regarding circulating biomarkers for cardiac SSc. Here, we aimed to investigate potential associations between cardiac SSc and candidate serum markers. Serum samples from patients of the Oslo University SSc cohort and 100 healthy controls were screened against two custom-made candidate marker panels containing molecules deemed relevant for cardiopulmonary and/or fibrotic diseases. Left (LV) and right ventricular (RV) dysfunction was assessed by protocol echocardiography, performed within three years from serum sampling. Patients suspected of pulmonary hypertension underwent right heart catheterization. Vital status at study end was available for all patients. Descriptive analyses, logistic and Cox regressions were conducted to assess associations between cardiac SSc and candidate serum markers. The 371 patients presented an average age of 57.2 (± 13.9) years. Female sex (84%) and limited cutaneous SSc (73%) were predominant. Association between LV diastolic dysfunction and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (OR 0.41, 95% CI 0.21-0.78, p = 0.007) was identified. LV systolic dysfunction defined by global longitudinal strain was associated with angiopoietin 2 (ANGPT2) (OR 3.42, 95% CI 1.52-7.71, p = 0.003) and osteopontin (OPN) (OR 1.95, 95% CI 1.08-3.52, p = 0.026). RV systolic dysfunction, measured by tricuspid annular plane systolic excursion, was associated to markers of LV dysfunction (ANGPT2, OPN, and TRAIL) (OR 1.67, 95% CI 1.11-2.50, p = 0.014, OR 1.86, 95% CI 1.25-2.77, p = 0.002, OR 0.32, 95% CI 0.15-0.66, p = 0.002, respectively) and endostatin (OR 1.86, 95% CI 1.22-2.84, p = 0.004). In conclusion, ANGPT2, OPN and TRAIL seem to be circulating biomarkers associated with both LV and RV dysfunction in SSc.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje